Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: A comparative study

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages

  Yao, Junxia ^a,d   Bechter, Clemens ^a   Wiesneth, Markus ^a,b   Härter, Georg ^a   Götz, Marlies ^a   Germeroth, Lothar ^c   Guillaume, Philippe ^e   Hasan, Ferishte ^a   Von Harsdorf, Stephanie ^a   Mertens, Thomas ^a   Michel, Detlef ^a   Döhner, Hartmut ^a   Bunjes, Donald ^a   Schmitt, Michael ^a   Schmitt, Anita ^a  

^a UNIVERSITY OF ULM   (Germany)

^b German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^c IBA GmbH   (Germany)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; PENTAMER; POLYMER; STREPTAMER; TETRAMER; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FLOW CYTOMETRY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STAINING; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; BLOOD; CHEMISTRY; EVALUATION; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METHODOLOGY; MIDDLE AGED;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; VIRAL MATRIX PROTEINS;

EID: 43249131226     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587749     Document Type: Article

References (31)

1. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102:4255-60.
2. Haerter G, Manfras BJ, de Jong-Hesse Y, et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004; 39:e88-94.
3. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor of pp65-specific CTL. J Virol 1996; 70:7569-79.
4. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52:165-73.
5. + virus specific cytotoxic T lymphocytes. J Med Virol 1994; 43:103-10.
6. Hebart H, Rauser G, Stevanovic S, et al. A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal immune responses in patients after allogeneic stem cell transplantation. Exp Hematol 2003; 31:966-73.
7. Duplan V, Suberbielle E, Napper CE, Joly E, Saoudi A, Gonzalez-Dunia D. Tracking antigen-specific CD8+ T cells in the rat using MHC class I multimers. J Immunol Methods 2007; 320:30-9.
8. Knabel M, Franz TJ, Schiemann M, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8:631-7.
9. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005; 106:938-45.
10. Li L, Reinhardt P, Schmitt A, et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 2005; 54:685-93.
11. Broers AE, Van Der Holt R, Van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95:2240-5.
12. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153:478-88.
13. Bacigalupo A, Tedone E, Sanna MA, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992; 77:507-13.
14. Takenaka K, Gondo H, Tanimoto K, et al.; The Fukuoka Bone Marrow Transplantation Group. Increased incidence of cytomegalovirus(CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997; 19:241-8.
15. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112:228-36.
16. Çelebi H, Dalva K, Özhan M, Beksaç M. Cytomegalovirus antigenemia is observed more frequently following allogeneic peripheral blood stem cell transplantation compared to bone marrow transplantation. Turk J Hematol 2006; 23:104-10.
17. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118:173-8.
18. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343:749-53.
19. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118:179-84.
20. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86:2815-20.
21. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21:597-605.
22. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80:1358-64.
23. Martinez C, Urbano-Ispizua A, Rovira M, Carreras E, Rozman C, Montserrat E. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation. Leuk Lymphoma 2000; 37:535-42.
24. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324:1005-11.
25. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-7.
26. Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995; 60:1473-7.
27. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation: international valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med 1999; 340:1462-70.
28. Voss S, Skerra A. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng 1997; 10:975-82.
29. Neudorfer J, Schmidt B, Huster KM, et al. Reversible HLA multimers (streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007; 320:119-31.
30. Grigoleit GU, Kapp M, Hebart H, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 2007; 196:699-704.
31. Manley TJ, Yamamoto T, Luy L, et al. Viral genome scan for analysis of CMV-specific CD8+ T cells in normal and immunocompromised individuals. Blood 2007; 110:1068.